Thromboembolism during Hormone Therapy in Japanese Women

ABSTRACT

Japanese women are unaccustomed to taking hormone therapies such as oral contraceptives (OCs) and hormone replacement therapy (HRT); therefore, there are few studies associated with hormone treatment in Japan. This study focused on evaluating thromboembolism during hormone therapy in Japanese women. In February 2002, we mailed questionnaires regarding the monthly average number of patients who had received prescriptions for OCs and HRT, and the incidence of arterial and venous thromboemboli during hormone therapy for the last 10 years. The mailings were sent to hospitals and clinics that are registered as monitoring institutions with the Japan Association of Obstetricians and Gynecologists. Of 1083 institutes, 771 responded (71% response rate). In July 2002, to obtain additional information on hormone therapy, patient history, and outcomes, we sent follow-up questionnaires to 39 institutions that responded as having experienced cases of thromboembolism. Thirty-nine institutions (5.1% of institutions responding to survey) experienced 53 cases of thromboembolism during hormone therapy. The 53 patients included 29 who received OCs (OC patients), 13 who received HRT (HRT patients), and 11 who received other hormone treatment. Among the 29 OC patients, eight had been diagnosed as having arterial thromboembolism (ATE), including two patients with myocardial infarction (MI) and six with ischemic stroke, whereas 20 had venous thromboembolism (VTE), including two with pulmonary embolism (PE) The remaining patient had an unknown thromboembolic event. Of the OC patients, 75.9% had a thromboembolism within the first year, and 58.6% patients were in their 40s. In 13 HRT patients, seven had ATE, including two MI patients and three with ischemic brain stroke, whereas six had VTE, including one PE patient. The duration of HRT varied widely from less than 1 year to more than 3 years; moreover, the HRT type did not affect thromboembolism occurrence. More than 70% of ATE patients and less than one third of VTE patients had to be hospitalized for the treatment of thromboembolism, and more than 75% of VTE patients recovered completely. However, one third of the ATE patients recovered with mild sequelae, one OC patient had severe sequelae due to stroke, and another OC patient died due to an ischemic event. The estimated incidence of thromboembolism in OC patients and HRT patients was 3.6 to 14.4 and 1.7 to 3.4 per 100,000 woman-years, respectively. The risk factors of thromboembolism, which were found consistently in this study, included obesity, smoking, lifestyle, and aging. Approximately 95% of institutions had not experienced thromboembolism in their hormone therapy patients, suggesting the incidence of thromboembolism during hormone therapy might be low. However, according to an analysis of risk factors, screening users of hormone supplements may be essential for providing safe hormone therapy. Moreover, because of the early occurrence of thromboembolism during hormone therapy, especially with OCs, it is important to monitor and instruct patients with caution from immediately after therapy initiation.

Oral contraceptives - hormone replacement therapy - myocardial infarction - ischemic brain stroke - venous thromboembolism

REFERENCES

• 1 Anonymous .Report of the survey on men's and women's life and the consciousness. Joint research project by the Ministry of Health, Labor and Welfare, and the Japan Family Planning Association. 2002 ed Tokyo; Japan Family Planning Association 2003: 59-61
• 2 Ouchi Y. Investigation on Japanese women's consciousness of hormone replacement therapy. The guideline of hormone replacement therapy in postmenopausal women for health promotion Tokyo; Medical Review Commission 2001: 197-204
• 3 Maternal and child health statistics of Japan. Tokyo; Maternal and Child Health Division, Equal Employment, Children and Families Bureau, Ministry of Health, Labour and Welfare 2002: 77-78
• 4 Satoh A, Diamaru O, Magaki R et al.. Pulmonary thromboembolism that developed during an airplane flight “economy-class syndrome” [In Japanese].  Nihon Kokyuki Gakkai Zasshi. 1998;  36 524-530
• 5 Adachi T. The survey on the actual condition of low-dose oral contraceptives in Japan for 4 years after the sale in 1999. Paper presented at: 105th annual meeting of the Japan society of obstetries and Gynecology 2003
• 6 Royal College of General Practitioners . Contracaptives, verous thrombosis, and varicose veins.  J R Coll Gen Pract. 1978;  192 393-399
• 7 Inman W HW, Vessey M P, Westerholm B et al.. Thromboembolic disease and the steroidal content of oral contraceptives.  BMJ. 1970;  2 203-209
• 8 Royal College of General Practitioners . Incidence of arterial disease among oral contraceptive users.  J R Coll Gen Pract. 1983;  33 75-82
• 9 Mann J I, Inman W HW. Oral contraceptives and death from myocardial infarction.  BMJ. 1975;  2 245-248
• 10 Mishell Jr D R. Oral contraception: past, present, and future perspectives.  Int J Fertil. 1991;  36(suppl) 7-18
• 11 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables.  Thromb Haemost. 1997;  78 315-326
• 12 Henkens C MA, Bom V JJ, Seinen A J et al.. Sensitivities to activated protein C: influence of oral contraceptives and sex.  Thromb Haemost. 1995;  73 402-404
• 13 Olivieri O, Friso S, Manzato F et al.. Resistance to activated protein C in healthy women taking oral contraceptives.  Br J Haematol. 1995;  91 465-470
• 14 Yasui T, Uemura H, Yoneda N et al.. Assessment of serum estrogen levels by RIA with HPLC during hormone replacement therapy.  Nippon Sanka Fujinka Gakkai Zasshi. 1995;  47 655-661
• 15 Kouno S. Phase I study of estradiol TTS-multiple application test.  J Clin Therapeutics Meds [Japanese]. 1992;  8 1819-1833
• 16 Mandel F P, Geola F L, Lu J KH et al.. Biologic effects of various doses of ethinylestradiol in postmenopausal women.  Obstet Gynecol. 1982;  59 673-679
• 17 Ouchi Y. Difference of sex steroid hormone agents between hormone replacement therapy and oral contraceptives. The guideline of hormone replacement therapy in postmenopausal women for health promotion Tokyo; Medical Review Commission 2001: 178-184
• 18 Dickey R P. Managing Contraceptive Pill Patient, 9th ed. New Orleans; Essential Medical Information Systems, Inc. 1998: 142-149
• 19 Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. American Heart Association.  Circulation. 1994;  89 1449-1468
• 20 Vessey M P, Mant D S, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study.  BMJ. 1986;  292 526-531
• 21 Farmer R DT, Preston T D. The risk of venous thromboembolism associated with low estrogen oral contraceptives.  J Obstet Gynecol. 1995;  00 195-200
• 22 Farley T MM, Collins J, Schlesselman J J. Hormonal contraception and risk of cardiovascular disease. An international perspective.  Contraception. 1998;  57 211-230
• 23 Rossouw J E. Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial.  JAMA. 2002;  288 321-333
• 24 The Guideline of Low-Dose Oral Contraceptive Use. Tokyo; Society of Japan Obstetrics and Gynecology, Shindantochiryousha 1999